# Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

Source: https://onco.cc/trials/nct06801236/  
OnCo record `nct06801236` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of ACE-232 run by Acerand Therapeutics (Hong Kong) Limited, now recruiting.

## Summary

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer is a phase 1 interventional study registered as NCT06801236 by Acerand Therapeutics (Hong Kong) Limited, with 88 participants planned, started 2025-05-12. Conditions recorded: Prostate Cancer (Adenocarcinoma) and mCRPC (Metastatic Castration-resistant Prostate Cancer). Interventions recorded: ACE-232 tablets.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06801236
- Phase: 1
- Setting: A Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ACE-232 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC)
- Sponsor: Acerand Therapeutics (Hong Kong) Limited
- Enrolled: 88

## Sources

- ClinicalTrials.gov NCT06801236: https://clinicaltrials.gov/study/NCT06801236

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [ACE-232](https://onco.cc/drugs/ace-232/)
- companies: [Acerand Therapeutics](https://onco.cc/companies/acerand-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06801236.json